Liminatus Pharma receives and resolves Nasdaq non-compliance for late 10-Q filing

Liminatus Pharma, Inc.

Received Nasdaq notice on May 29, 2025, for non-compliance with Listing Rule 5250(c)(1) due to delayed Form 10-Q.
Filed the overdue Form 10-Q for Q1 2025 on June 2, 2025.
Nasdaq confirmed on June 3, 2025, that the company regained compliance; matter is closed.
Pre-clinical biotech (LIMN) focuses on immune-modulating cancer therapies.

item 3.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.